Technology | January 19, 2011

GE to Distribute Interventional Oncology Navigation Systems

January 19, 2011 – GE Healthcare and Veran announced a strategic supplier agreement this week in which GE became the exclusive distributor and reseller of Veran’s ig4 fusion imaging angiography navigation system in the United States.

The deal brings together GE’s Innova angiography imaging systems and Veran’s electromagnetic navigation to create a comprehensive interventional oncology solution under a single point of contact. The system allows 4-D registration capability with for precise targeting of cancerous lesions.

The multimodality Veran ig4 system helps clinicians deliver instruments to small targets in difficult to access regions of the human body in order to diagnose and treat disease minimally invasively. The navigation system uses electromagnetic localization and 4-D (x, y, z time) registration to display an interventional instrument, such as a biopsy needle or ablation needle, on a computer monitor with respect to anatomic imaging and treatment planning.

This system is compatible with GE’s Innova imaging systems, which acquire CT-like patient images of the target organ(s) that can be exported to the navigation system in the same imaging suite, during the interventional procedure. The resulting displayed image provides navigation information to help physicians insert biopsy needles, ablation (radio frequency (RF), cryotherapy and microwave) probes and other devices through the skin more quickly and with greater target accuracy. Also, using Innova CT images with Veran ig4 system may help to reduce the absorbed radiation dose through decreased use of fluoroscopy.

“This is exciting news for our customers who want to perform complex procedures in a timely fashion with more confidence. The combined systems can help clinicians achieve greater accuracy, perform procedures more quickly and reduce radiation dose,” said Chantal Le Chat, general manager of interventional radiology, GE Healthcare.

”Partnering with a global company such as GE Healthcare to significantly increase the access of our cutting edge 4-D registration technology is a great step forward for Veran Medical,” said Jerome R. Edwards, president and CEO, Veran Medical Technologies. “GE Healthcare’s healthymagination vision is extremely synergistic with the mission that Veran Medical has by having its focus directed in the interventional oncology market.”

For more information: www.gehealthcare.com, www.veranmedical.com

Related Content

Boston Scientific Closes Acquisition of BTG plc
News | Interventional Radiology | August 20, 2019
Boston Scientific Corp. announced the completion of its acquisition of BTG plc. pursuant to the previously announced...
First GammaTile Therapy Case Completed in Arizona
News | Radiation Therapy | August 19, 2019
HonorHealth Scottsdale Osborn Medical Center is the first hospital in Arizona to begin offering GammaTile Therapy, a...
Profound Medical Receives U.S. FDA 510(k) Clearance for Tulsa-Pro
Technology | Interventional Radiology | August 16, 2019
Profound Medical Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
Drug Accelerates Blood System's Recovery After Radiation, Chemotherapy

Following radiation, the bone marrow shows nearly complete loss of blood cells in mice (left). Mice treated with the PTP-sigma inhibitor displayed rapid recovery of blood cells (purple, right). Credit: UCLA Broad Stem Cell Research Center/Nature Communications

News | Radiation Therapy | August 16, 2019
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem...
Mevion and C-RAD Release Integration for Improved Proton Therapy Treatment Quality

Catalyst PT image courtesy of C-RAD

News | Patient Positioning Radiation Therapy | August 15, 2019
Mevion Medical Systems and C-RAD announced the integration between the C-RAD Catalyst PT and the Mevion S250i proton...
First Patient Enrolled in World's Largest Brain Cancer Clinical Trial
News | Radiation Therapy | August 15, 2019
Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive...
FDA Clears NvisionVLE Imaging System for Pancreatic and Biliary Applications

Image courtesy of NinePoint Medical

Technology | Interventional Radiology | August 14, 2019
August 14, 2019 — NinePoint Medical Inc. announced it has received U.S.
Efficacy of Isoray's Cesium Blu Showcased in Recent Studies
News | Brachytherapy Systems | August 14, 2019
August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica
MD Anderson to Expand Proton Therapy Center

The MD Anderson Proton Therapy Center expansion is expected to be completed in 2023. Rendering courtesy of Stantec.

News | Proton Therapy | August 08, 2019
The University of Texas MD Anderson Cancer Center unveiled plans to expand its Proton Therapy Center during a...